Visceral Pain Treatment Market: Ulcerative Colitis Segment to Witness Significant Growth

Visceral Pain Treatment Market: Introduction

Pain is experienced when internal organs and tissues are damaged or injured. Visceral pain occurs due to activation of nociceptors of the thoracic, pelvic, or abdominal viscera. Injuries to organs including gallbladder, intestines, bladder, or kidneys could cause visceral pain. Symptomatic treatment relies on use of medications such as painkillers, spasmolytics, and antidepressants.

Read Report Overview - https://www.transparencymarketresearch.com/visceral-pain-treatment-market.html

Key Drivers and Restraints of Global Visceral Pain Treatment Market

• Visceral pain associated with ailments such as inflammatory bowel diseases, gallstones, acute pancreatitis, acute appendicitis, and diverticulitis are the most common reasons for visits to outpatient and inpatient gastrointestinal (GI) clinics. High prevalence and increase in incidence of target diseases boost market growth. Inflammatory bowel diseases are most common in developed countries compared to developing countries. These diseases affect men and women alike and mostly affect people aged between 15 and 30. According to the Centers for Disease Control and Prevention (CDC), in 2015, nearly 3.1 million people (1.3% of the population) in the U.S. were diagnosed with either Crohn’s disease or ulcerative colitis. Each year around 70,000 new cases of IBD are diagnosed in the U.S. Hospitalization rate of secondary diagnosed population with IBD has increased significantly from 44.2 to 59.7 per 100,00 population during 2003–2013.
• Recent launch and approval of new drugs in North America, Europe, and Japan are projected to fuel demand for visceral pain treatment in the near future. AstraZeneca and Allergan are together developing MEDI2070 interleukin-23 monoclonal antibody against ulcerative colitis and Crohn’s disease. The MEDI2070 is currently in phase IIb of clinical trial for moderate to severe Crohn’s disease and in phase II for ulcerative colitis. Pfizer’s PF-00547659, and Celgene’s Ozanimod are in phase II and phase III clinical trials for Crohn’s disease and ulcerative colitis, respectively.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79458

• However, patent expiration of top drugs is anticipated hamper market growth in the near future. Most of the leading biologic and pharmaceutical products have lost their patents in the past few years and some are expected to go off patent in the near future. Therefore, generic and biosimilar medicines are likely to gain market share during the forecast period. Humira (Adalimumab), a leading biologic brand for the treatment of IBD from AbbVie, In., lost its patent in 2016. Johnson & Johnson’s Remicade lost patent in 2014. Newly launched biosimilar and generic treatment products have recorded exponential year-on-year growth rate and are projected to capture a major share of the market in the near future.

Analgesics Segment Dominated Global Visceral Pain Treatment Market

• In terms of drug type, the global visceral pain treatment market can be divided into pain modifiers, analgesics, and others. The pain modifiers segment can be split into tricyclic anticonvulsant and tricyclic antidepressants. The analgesics segment can be segregated into narcotics and NSAID.
• The analgesics segment held major market share in 2019. The first-line treatment of visceral pain is the use of non-opioid analgesics. Some over-the-counter non-steroidal anti-inflammatories (NSAIDs) category analgesic, which are primarily used in visceral pain treatment include Aleve (naproxen) and aspirin (acetylsalicylic acid). In August 2020, Lannett Company, Inc. announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, which is an opioid pain reliever, under the companies’ recently announced interim exclusive supply and distribution agreement. Baudax Bio launched as a new pharmaceutical company aimed at advancing promising, non-opioid analgesic therapies.

Request for Analysis of COVID-19 Impact on Visceral Pain Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79458

Ulcerative Colitis Segment to Witness Significant Growth

• Based on disease indication, the global visceral pain treatment market can be classified into chronic prostatitis, interstitial cystitis, Crohn’s disease, and ulcerative colitis
• The ulcerative colitis segment accounted for the largest share of the market in 2019, followed by the Crohn’s disease segment. Inflammatory bowel disease (IBD), including two subtypes, ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory disorder of unfamiliar etiology. Significant rise in prevalence and incidence of IBDs have been reported in the last few decades and are anticipated to increase during the forecast period. According to IBD Support Australia Incorporated, around 61,000 people in Australia are affected by inflammatory bowel disease, of which around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis.

Retail Pharmacies Segment to Lead Global Visceral Pain Treatment Market

• In terms of distribution channel, the global visceral pain treatment market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies
• The retail pharmacies segment held major market share in terms of revenue in 2019 and the trend is expected to continue during the forecast period. However, the online pharmacies segment is likely to expand at the highest CAGR from 2020 to 2030 due to increase in Internet penetration and smartphone ownership along with the ease of ordering medications through an e-commerce platform, rise in prevalence of chronic diseases, and surge in per capita income and resultant health care spend.
• The retail pharmacies segment witnessed significant growth in the past few years, owing to favorable demographic factors and an epidemiological transition. Inclusion of various medicines under the OTC category and preference for self-medication is projected to drive the segment.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79458

North America to Dominate Global Visceral Pain Treatment Market

• In terms of region, the global visceral pain treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
• In terms of revenue, North America dominated the global visceral pain treatment market in 2019 due to increase in awareness about visceral pain treatment and rise in government initiatives. Additionally, surge in investment in research & development by various pharmaceutical companies drives the market in North America. Neomed Management AS, Arena Pharmaceuticals, Inc., and Anavex Life Sciences Corp. are the major companies having drugs in the visceral pain therapeutic pipeline. Increase in incidence of diseases is also a major factor propelling the market in the region. Around 70,000 new cases of inflammatory bowel diseases (IBD) are diagnosed in the U.S. each year. There may be as many as 80,000 children in the country with IBD.
• Asia Pacific is likely to be a highly lucrative market for visceral pain treatment during the forecast period. The market in the region is projected to expand at a high CAGR from 2020 to 2030. Adoption of new treatment methods, pipeline drugs, and increase in partnership of governments with private players and clinical laboratories are anticipated to propel the market in Asia Pacific during the forecast period. According to data published in NCBI in 2016, incidence of ulcerative colitis was approximately 1 per 100,000 in Asia, while the incidence of Crohn’s disease was slightly lower, at approximately 0.5 per 100,000 people.

Pre Book Visceral Pain Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79458&ltype=S

Key Players Operating in Global Visceral Pain Treatment Market

The global visceral pain treatment market was highly fragmented in 2019. Key players operating in the global market are:

• Addex Therapeutics Ltd.
• AstraZeneca
• Astellas Pharma, Inc.
• Allergan
• Chromocell Corporation
• Takeda, GIcare Pharma, Inc.
• AbbVie
• Grunenthal GmbH
• Johnson & Johnson
• Neurim Pharmaceuticals Ltd.
• Medestea Research & Production S.p.A.

Browse more Trending by Transparency Market Research:

Healthcare CRM Market: https://www.transparencymarketresearch.com/healthcare-crm-market.html

Colposcopy Market: https://www.transparencymarketresearch.com/colposcopy-market.html

Continuing Medical Education Market: https://www.transparencymarketresearch.com/continuing-medical-education-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/